Hui-rong Pan
Xiamen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial.
Journal: The Lancet. Infectious diseases
Published: March 14, 2023
Safety and immunogenicity of an Escherichia coli-produced 9-valent human papillomavirus L1 virus-like particle vaccine (types 6/11/16/18/31/33/45/52/58) in healthy adults: an open-label, dose-escalation phase 1 clinical trial.
Journal: The Lancet regional health. Western Pacific
Published: February 06, 2023
Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial.
Journal: Human vaccines & immunotherapeutics
Published: July 14, 2022
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
Journal: The Lancet. Infectious diseases
Published: April 18, 2022
Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response.
Journal: Emerging microbes & infections
Published: February 15, 2021
Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals.
Journal: Human vaccines & immunotherapeutics
Published: June 17, 2020
Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial.
Journal: Human vaccines & immunotherapeutics
Published: November 27, 2019
Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women.
Journal: Science China. Life sciences
Published: March 12, 2019
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.
Journal: Journal of the National Cancer Institute
Published: January 15, 2019
Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years.
Journal: Vaccine
Published: October 09, 2018
Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial.
Journal: Vaccine
Published: May 03, 2015
Long-term efficacy of a hepatitis E vaccine.
Journal: The New England journal of medicine
Published: March 05, 2015
Last Updated: 09/26/2026